keyword
MENU ▼
Read by QxMD icon Read
search

dementia with lewy bodies and Parkinson's

keyword
https://www.readbyqxmd.com/read/29780124/hiv-dementia-with-a-decreased-cardiac-123-i-metaiodobenzylguanidine-uptake-masquerading-as-dementia-with-lewy-bodies
#1
Masanori Kurihara, Takuya Sasaki, Hiroyuki Ishiura, Shoji Tsuji
Cardiac 123 I-metaiodobenzylguanidine (MIBG) scintigraphy is a promising biomarker for dementia with Lewy bodies (DLB). However, we experienced a patient with cognitive decline, parkinsonism, and a decreased MIBG uptake who turned out to have HIV dementia. Normal dopamine transporter single-photon emission computed tomography reduced the possibility of comorbid Lewy body pathology causing the patient' s parkinsonism. The decreased MIBG uptake was most likely due to postganglionic sympathetic nerve denervation, which can also be caused by HIV...
May 18, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29764386/parkinson-s-disease-diagnostic-observations-paddo-study-rationale-and-design-of-a-prospective-cohort-study-for-early-differentiation-of-parkinsonism
#2
Anouke van Rumund, Marjolein B Aerts, Rianne A J Esselink, Frederick J A Meijer, Marcel M Verbeek, Bastiaan R Bloem
BACKGROUND: Differentiation of Parkinson's disease (PD) from the various types of atypical parkinsonism (AP) such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), corticobasal syndrome (CBS) and vascular parkinsonism (VP), can be challenging, especially early in the disease course when symptoms overlap. A major unmet need in the diagnostic workup of these disorders is a diagnostic tool that differentiates the various disorders, preferably in the earliest disease stages when the clinical presentation is similar...
May 16, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29761296/neuroimaging-in-lewy-body-dementia
#3
REVIEW
Tayyabah Yousaf, George Dervenoulas, Polytimi-Eleni Valkimadi, Marios Politis
Lewy body dementia (DLB) is a common form of cognitive impairment, accounting for 30% of dementia cases in ages over 65 years. Early diagnosis of DLB has been challenging; particularly in the context of differentiation with Parkinson's disease dementia and other forms of dementias, such as Alzheimer's disease and rapidly progressive dementias. Current practice involves the use of [123 I]FP-CIT-SPECT, [18 F]FDG PET and [123 I]MIBG molecular imaging to support diagnostic procedures. Structural imaging techniques have an essential role for excluding structural causes, which could lead to a DLB-like phenotype, as well as aiding differential diagnosis through illustrating disease-specific patterns of atrophy...
May 14, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29760287/-multi-organ-distribution-of-alpha-synuclein-pathology-in-dementia-with-lewy-bodies
#4
Koichi Wakabayashi, Yasuo Miki
In Parkinson's disease and dementia with Lewy bodies, neuronal α-synuclein aggregates (Lewy bodies and Lewy neurites) are distributed throughout the nervous system, including the brain, spinal cord, sympathetic ganglia, enteric nervous system, cardiac and pelvic plexuses, submandibular gland, adrenal medulla, and skin. Lewy bodies also occur in 10-20% of neurologically asymptomatic individuals older than 60 years. These cases are called incidental Lewy body disease (ILBD). In ILBD, Lewy bodies can be found in the brain, spinal cord, sympathetic ganglia, visceral autonomic nervous system and skin...
May 2018: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/29759483/induction-of-the-immunoproteasome-subunit-lmp7-links-proteostasis-and-immunity-in-%C3%AE-synuclein-aggregation-disorders
#5
Scott Ugras, Malcolm J Daniels, Hossein Fazelinia, Neal S Gould, Anastasia K Yocum, Kelvin C Luk, Esteban Luna, Hua Ding, Chris McKennan, Steven Seeholzer, Dan Martinez, Perry Evans, Daniel Brown, John E Duda, Harry Ischiropoulos
Accumulation of aggregated α-synuclein into Lewy bodies is thought to contribute to the onset and progression of dopaminergic neuron degeneration in Parkinson's disease (PD) and related disorders. Although protein aggregation is associated with perturbation of proteostasis, how α-synuclein aggregation affects the brain proteome and signaling remains uncertain. In a mouse model of α-synuclein aggregation, 6% of 6215 proteins and 1.6% of 8183 phosphopeptides changed in abundance, indicating conservation of proteostasis and phosphorylation signaling...
May 11, 2018: EBioMedicine
https://www.readbyqxmd.com/read/29756641/full-sequencing-and-haplotype-analysis-of-mapt-in-parkinson-s-disease-and-rapid-eye-movement-sleep-behavior-disorder
#6
Jiao Li, Jennifer A Ruskey, Isabelle Arnulf, Yves Dauvilliers, Michele T M Hu, Birgit Högl, Claire S Leblond, Sirui Zhou, Amirthagowri Ambalavanan, Jay P Ross, Cynthia V Bourassa, Dan Spiegelman, Sandra B Laurent, Ambra Stefani, Christelle Charley Monaca, Valérie Cochen De Cock, Michel Boivin, Luigi Ferini-Strambi, Giuseppe Plazzi, Elena Antelmi, Peter Young, Anna Heidbreder, Catherine Labbe, Tanis J Ferman, Patrick A Dion, Dongsheng Fan, Alex Desautels, Jean-François Gagnon, Nicolas Dupré, Edward A Fon, Jacques Y Montplaisir, Bradley F Boeve, Ronald B Postuma, Guy A Rouleau, Owen A Ross, Ziv Gan-Or
BACKGROUND: MAPT haplotypes are associated with PD, but their association with rapid eye movement sleep behavior disorder is unclear. OBJECTIVE: To study the role of MAPT variants in rapid eye movement sleep behavior disorder. METHODS: Two cohorts were included: (A) PD (n = 600), rapid eye movement sleep behavior disorder (n = 613) patients, and controls (n = 981); (B) dementia with Lewy bodies patients with rapid eye movement sleep behavior disorder (n = 271) and controls (n = 950)...
May 14, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29755341/plasma-biomarkers-differentiate-parkinson-s-disease-from-atypical-parkinsonism-syndromes
#7
Chin-Hsien Lin, Shieh-Yueh Yang, Herng-Er Horng, Che-Chuan Yang, Jen-Jie Chieh, Hsin-Hsien Chen, Bing-Hsien Liu, Ming-Jang Chiu
Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples ( n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism...
2018: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/29743672/cellular-milieu-imparts-distinct-pathological-%C3%AE-synuclein-strains-in-%C3%AE-synucleinopathies
#8
Chao Peng, Ronald J Gathagan, Dustin J Covell, Coraima Medellin, Anna Stieber, John L Robinson, Bin Zhang, Rose M Pitkin, Modupe F Olufemi, Kelvin C Luk, John Q Trojanowski, Virginia M-Y Lee
In Lewy body diseases-including Parkinson's disease, without or with dementia, dementia with Lewy bodies, and Alzheimer's disease with Lewy body co-pathology 1 -α-synuclein (α-Syn) aggregates in neurons as Lewy bodies and Lewy neurites 2 . By contrast, in multiple system atrophy α-Syn accumulates mainly in oligodendrocytes as glial cytoplasmic inclusions (GCIs) 3 . Here we report that pathological α-Syn in GCIs and Lewy bodies (GCI-α-Syn and LB-α-Syn, respectively) is conformationally and biologically distinct...
May 9, 2018: Nature
https://www.readbyqxmd.com/read/29742972/validity-and-clinical-utility-of-different-clock-drawing-test-scoring-systems-in-multiple-forms-of-dementia
#9
Diana Duro, Miguel Tábuas-Pereira, Sandra Freitas, Beatriz Santiago, Maria Amália Botelho, Isabel Santana
The Clock Drawing Test (CDT) has a known potential for the detection of cognitive impairment in populations with dementia, especially Alzheimer disease (AD). Our aim was to compare the clinical utility of 3 CDT scoring systems (Rouleau, Cahn, and Babins) in several pathologies with cognitive compromise from a tertiary center memory clinic. We selected patients with a clinical diagnosis of mild stage AD, behavioral variant frontotemporal dementia (FTD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and Parkinson disease with dementia (PDD)...
January 1, 2018: Journal of Geriatric Psychiatry and Neurology
https://www.readbyqxmd.com/read/29738880/the-interaction-of-%C3%AE-synuclein-and-tau-a-molecular-conspiracy-in-neurodegeneration
#10
REVIEW
Xu Yan, Riikka-Liisa Uronen, Henri J Huttunen
α-synuclein and Tau are proteins prone to pathological misfolding and aggregation that are normally found in the presynaptic and axonal compartments of neurons. Misfolding initiates a homo-oligomerization and aggregation cascade culminating in cerebral accumulation of aggregated α-synuclein and Tau in insoluble protein inclusions in multiple neurodegenerative diseases. Traditionally, α-synuclein-containing Lewy bodies have been associated with Parkinson's disease and Tau-containing neurofibrillary tangles with Alzheimer's disease and various frontotemporal dementia syndromes...
May 5, 2018: Seminars in Cell & Developmental Biology
https://www.readbyqxmd.com/read/29737566/phosphorylated-%C3%AE-synuclein-in-the-retina-is-a-biomarker-of-parkinson-s-disease-pathology-severity
#11
Isabel Ortuño-Lizarán, Thomas G Beach, Geidy E Serrano, Douglas G Walker, Charles H Adler, Nicolás Cuenca
BACKGROUND: PD patients often have visual alterations, for example, loss of visual acuity, contrast sensitivity or motion perception, and diminished electroretinogram responses. PD pathology is mainly characterized by the accumulation of pathological α-synuclein deposits in the brain, but little is known about how synucleinopathy affects the retina. OBJECTIVE: To study the correlation between α-synuclein deposits in the retina and brain of autopsied subjects with PD and incidental Lewy body disease...
May 8, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29735655/soluble-epoxide-hydrolase-plays-a-key-role-in-the-pathogenesis-of-parkinson-s-disease
#12
Qian Ren, Min Ma, Jun Yang, Risa Nonaka, Akihiro Yamaguchi, Kei-Ichi Ishikawa, Kenta Kobayashi, Shigeo Murayama, Sung Hee Hwang, Shinji Saiki, Wado Akamatsu, Nobutaka Hattori, Bruce D Hammock, Kenji Hashimoto
Parkinson's disease (PD) is characterized as a chronic and progressive neurodegenerative disorder, and the deposition of specific protein aggregates of α-synuclein, termed Lewy bodies, is evident in multiple brain regions of PD patients. Although there are several available medications to treat PD symptoms, these medications do not prevent the progression of the disease. Soluble epoxide hydrolase (sEH) plays a key role in inflammation associated with the pathogenesis of PD. Here we found that MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced neurotoxicity in the mouse striatum was attenuated by subsequent repeated administration of TPPU, a potent sEH inhibitor...
May 7, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29734182/a-systematic-review-and-meta-analysis-of-the-effectiveness-of-acetylcholinesterase-inhibitors-and-memantine-in-treating-the-cognitive-symptoms-of-dementia
#13
Ruth Knight, Mizanur Khondoker, Nicholas Magill, Robert Stewart, Sabine Landau
BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. SUMMARY: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2...
May 7, 2018: Dementia and Geriatric Cognitive Disorders
https://www.readbyqxmd.com/read/29730823/the-correlation-between-striatal-and-cortical-binding-ratio-of-11-c-pib-pet-in-amyloid-uptake-positive-patients
#14
Julia Sauerbeck, Kazunari Ishii, Chisa Hosokawa, Hayato Kaida, Franziska T Scheiwein, Kohei Hanaoka, Axel Rominger, Matthias Brendel, Peter Bartenstein, Takamichi Murakami
PURPOSE: In subjects with amyloid deposition, striatal accumulation of 11 C-Pittsburgh compound B (PiB) demonstrated by positron emission tomography (PET) is related to the stage of Alzheimer's disease (AD). In this study, we investigated the correlation between striatal and cortical non-displaceable binding potential (BPND ). METHODS: Seventy-three subjects who complained of cognitive disturbance underwent dynamic PiB-PET studies and showed positive PiB accumulation were retrospectively selected...
May 5, 2018: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29716652/%C3%AE-synuclein-fibril-induced-paradoxical-structural-and-functional-defects-in-hippocampal-neurons
#15
Jessica M Froula, Benjamin W Henderson, Jose Carlos Gonzalez, Jada H Vaden, John W Mclean, Yumei Wu, Gokulakrishna Banumurthy, Linda Overstreet-Wadiche, Jeremy H Herskowitz, Laura A Volpicelli-Daley
Neuronal inclusions composed of α-synuclein (α-syn) characterize Parkinson's Disease (PD) and Dementia with Lewy bodies (DLB). Cognitive dysfunction defines DLB, and up to 80% of PD patients develop dementia. α-Syn inclusions are abundant in the hippocampus, yet functional consequences are unclear. To determine if pathologic α-syn causes neuronal defects, we induced endogenous α-syn to form inclusions resembling those found in diseased brains by treating hippocampal neurons with α-syn fibrils. At seven days after adding fibrils, α-syn inclusions are abundant in axons, but there is no cell death at this time point, allowing us to assess for potential alterations in neuronal function that are not caused by neuron death...
May 1, 2018: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/29709939/a-case-of-fatal-familial-insomnia-initially-developing-parkinsonism-mimicking-dementia-with-lewy-bodies
#16
Takuya Fukuoka, Yoshihiko Nakazato, Masaomi Yamamoto, Akifumi Miyake, Takashi Mitsufuji, Toshimasa Yamamoto
We report a rare case of fatal familial insomnia in a 58-year-old man who initially developed parkinsonism, secondary dementia, and visual hallucinations that were suspected to be due to dementia with Lewy bodies. We evaluated the function of the striatum via dopamine transporter SPECT using 123 I-ioflupane and found marked presynaptic dopamine dysfunction in the bilateral striatum. This is the first reported case in which the initial symptom of fatal familial insomnia was parkinsonism and in which the dopamine transporter function was evaluated by DAT SPECT...
April 27, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29704213/%C3%A9-synuclein-strains-and-seeding-in-parkinson-s-disease-incidental-lewy-body-disease-dementia-with-lewy-bodies-and-multiple-system-atrophy-similarities-and-differences
#17
REVIEW
W Peelaerts, L Bousset, V Baekelandt, R Melki
Several age-related neurodegenerative disorders are characterized by the deposition of aberrantly folded endogenous proteins. These proteins have prion-like propagation and amplification properties but so far appear nontransmissible between individuals. Because of the features they share with the prion protein, PrP, the characteristics of pathogenic protein aggregates in several progressive brain disorders, including different types of Lewy body diseases (LBDs), such as Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB), have been actively investigated...
April 27, 2018: Cell and Tissue Research
https://www.readbyqxmd.com/read/29703245/d409h-gba1-mutation-accelerates-the-progression-of-pathology-in-a53t-%C3%AE-synuclein-transgenic-mouse-model
#18
Donghoon Kim, Heehong Hwang, Seulah Choi, Sang Ho Kwon, Suhyun Lee, Jae Hong Park, SangMin Kim, Han Seok Ko
Heterozygous mutations in glucocerebrosidase 1 (GBA1) are a major genetic risk factor for Parkinson's disease and Dementia with Lewy bodies. Mutations in GBA1 leads to GBA1 enzyme deficiency, and GBA1-associated parkinsonism has an earlier age of onset and more progressive parkinsonism. To investigate a potential influence of GBA1 deficiency caused by mutations in GBA1 on the disease progression of PD, GBA1 mice carrying D409H knock-in mutation were crossbred with the human A53T (hA53T) α-synuclein transgenic mice...
April 27, 2018: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/29692703/pleiotropic-effects-of-variants-in-dementia-genes-in-parkinson-disease
#19
Laura Ibanez, Umber Dube, Albert A Davis, Maria V Fernandez, John Budde, Breanna Cooper, Monica Diez-Fairen, Sara Ortega-Cubero, Pau Pastor, Joel S Perlmutter, Carlos Cruchaga, Bruno A Benitez
Background: The prevalence of dementia in Parkinson disease (PD) increases dramatically with advancing age, approaching 80% in patients who survive 20 years with the disease. Increasing evidence suggests clinical, pathological and genetic overlap between Alzheimer disease, dementia with Lewy bodies and frontotemporal dementia with PD. However, the contribution of the dementia-causing genes to PD risk, cognitive impairment and dementia in PD is not fully established. Objective: To assess the contribution of coding variants in Mendelian dementia-causing genes on the risk of developing PD and the effect on cognitive performance of PD patients...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29684335/emergence-of-breath-testing-as-a-new-non-invasive-diagnostic-modality-for-neurodegenerative-diseases
#20
REVIEW
N Siva Subramaniam, C S Bawden, H Waldvogel, R M L Faull, G S Howarth, R G Snell
Neurodegenerative diseases (NDDs) are incapacitating disorders that result in progressive motor and cognitive impairment. These disease include Alzheimer's disease the most common cause of dementia, frontotemporal dementia, amyotrophic lateral sclerosis, dementia with Lewy bodies, Parkinson's, Huntington's, Friedreich's ataxia, and prion disease. Dementia causing NDDs impose a high social and economic burden on communities around the world. Rapid growth in knowledge regarding the pathogenic mechanisms and disease-associated biomarkers of these diseases in the past few decades have accelerated the development of new diagnostic methods and therapeutic opportunities...
April 20, 2018: Brain Research
keyword
keyword
60034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"